High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study

Eur J Surg Oncol. 2012 Aug;38(8):683-91. doi: 10.1016/j.ejso.2012.04.010. Epub 2012 May 22.

Abstract

Purpose: The aim of this prospective cohort study was to investigate the impact of preoperative hepatitis B viral load, as well as postoperative antiviral therapy, on the risk of long-term survival after curative resection of hepatitis B virus-related hepatocellular carcinoma (HCC).

Methods: A prospective cohort of hepatitis B virus-related HCC patients undergoing curative resection from 2002 to 2008 was studied. According to preoperative viral load (using 10,000 copies/mL of hepatitis B virus DNA level as cut-off value), two groups were compared. Prognostic factors for overall survival and recurrence-free survival were evaluated. Additionally, subgroup analysis was conducted in patients with high viral load to investigate prediction of postoperative antiviral therapy on the long-term prognosis.

Results: With a median follow-up of 49.1 months, patients with high viral load had lower median overall survival (78.3 months vs. 111.4 months, P<0.001) and RFS (44.6 months vs. 94.8 months, P<0.001) compared with those with low viral load. Multivariate analysis revealed that preoperative high viral load was an independent risk factor affecting both overall survival and recurrence-free survival (both P<0.001). The subgroup analysis revealed that postoperative antiviral therapy independently improved recurrence-free survival for patients with high viral load (P=0.001).

Conclusions: Hepatitis B virus-related HCC patients with preoperative high viral load led to poorer overall and recurrence-free survival than those with low viral load after curative resection. To prevent postoperative recurrence, antiviral therapy should be initiated in those patients with hepatitis B virus DNA ≥ 10,000 copies/ml.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / therapeutic use*
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / surgery
  • Carcinoma, Hepatocellular / virology*
  • Child
  • China / epidemiology
  • DNA, Viral / analysis
  • Female
  • Follow-Up Studies
  • Hepatectomy
  • Hepatitis B / drug therapy
  • Hepatitis B / mortality
  • Hepatitis B / virology*
  • Hepatitis B Antibodies / immunology
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology
  • Hepatitis B virus / isolation & purification*
  • Humans
  • Liver Neoplasms / mortality
  • Liver Neoplasms / surgery
  • Liver Neoplasms / virology*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / epidemiology*
  • Prognosis
  • Prospective Studies
  • Risk Factors
  • Time Factors
  • Viral Load*
  • Young Adult

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Antibodies